Island Pharmaceuticals Ltd (ILA)

Sydney
0.14
+0.01(+11.54%)
  • Volume:
    39,364
  • Bid/Ask:
    0.14/0.15
  • Day's Range:
    0.13 - 0.15

ILA Overview

Prev. Close
0.13
Day's Range
0.13-0.15
Revenue
-
Open
0.13
52 wk Range
0.12-0.38
EPS
-0.04
Volume
39,364
Market Cap
10.56M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
111,842
P/E Ratio
-
Beta
-
1-Year Change
-55.17%
Shares Outstanding
81,268,468
Next Earnings Date
-
What is your sentiment on Island Pharmaceuticals?
or
Market is currently closed. Voting is open during market hours.

Island Pharmaceuticals Ltd Company Profile

Island Pharmaceuticals Ltd Company Profile

Employees
0
Market
Australia

Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. Island Pharmaceuticals Limited has a research collaboration agreement with Monash University to screen known molecules against host targets; research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy; research collaboration agreement with Compounds Australia, a drug library containing approximately four and a half thousand molecules that could be searched for drug re-purposing and pipeline development; cooperative research and development agreement with the U.S. Army in preparation for its Phase II clinical study for ISLA-101; supply agreement with Catalent for manufacture of Fenretinide softgels for dengue fever trial participants; and right to reference National Cancer Institute IND for Isla101. The company was founded in 2017 and is based in Camberwell, Australia.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyBuySellSell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong SellStrong Sell